Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report specifically addresses the notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than providing general financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions.
Material Changes
The filing details changes in the interests of a connected person of Director Sir Andrew Witty:
- Sale: 737 Ordinary Shares sold on May 9, 2014, at 1614.5550p per share.
- Repurchase: 730 Ordinary Shares repurchased on May 12, 2014, at 1615.3900p per share.
- Transfer: The repurchased shares were transferred into an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly complies with paragraph 3.1.4R(1)(a) and (c) of the Disclosure and Transparency Rules regarding director transactions.
Investor Verification Points
- Verify the exact timing and pricing of the share transactions involving Sir Andrew Witty's connected person.
- Confirm the net change in shareholding (a reduction of 7 shares) for the connected person.
- Note that this filing does not contain operational or financial performance data for the period.